Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

54 participants living with HIV (PLWH) or without HIV (PLWoH) received 10E8.4/iMab or placebo.

In arm 1, PLWoH received 10E8.4/iMab 0.3 mg kg -1 intravenously, 1 mg kg -1 subcutaneously, or 1 mg kg -1 intravenously (n = 3 each).

In arm 2, PLWoH received 10E8.4/iMab 3 mg kg -1 intravenously, 10 mg kg -1 intravenously or 30 mg kg -1 intravenously (n = 6 each).

In arms 3/3a, PLWH received 10E8.4/iMab 10 mg kg -1 intravenously (n = 3) or 30 mg kg -1 intravenously (n = 6).